Edgewise Therapeutics (NASDAQ:EWTX) Receives “Buy” Rating from HC Wainwright
HC Wainwright reaffirmed a “buy” rating on Edgewise Therapeutics (NASDAQ:EWTX) in a Tuesday report, setting a $45.00 price target (about 32.3% above the prior close). The stock fell to $34.02 on Tuesday. The company reported Q1 EPS of -$0.46 versus -$0.50 consensus, and analysts forecast -2.01 EPS for the fiscal year.
How this was made
The 30-second read
Why it matters
This is primarily a sentiment/valuation update (reaffirmed Buy and a $45 target) rather than new clinical, regulatory, or financial guidance. Traders may treat it as incremental support but not a standalone catalyst.
Market read
A reiterated Buy with a specific upside target can influence short-term positioning, but the article lacks a new trial/regulatory/financing event.
What to watch
Insider selling (CMO Form 4) and the negative EPS outlook for the current fiscal year (-2.01) could cap upside if investors focus on fundamentals over price targets.
Background
Edgewise Therapeutics is a clinical-stage biopharma focused on TRPC5 inhibition (EWTX-101) for rare diseases, with the article summarizing recent analyst coverage and prior quarter results.
Ticker impact
HC Wainwright reaffirmed a “buy” rating and set a $45 price objective for Edgewise Therapeutics, implying ~32% upside from the prior close.
Likely supports near-term downside protection / modest bounce, with follow-through dependent on whether other firms’ targets cluster around the same range.
The only fresh, company-specific item here is the reiterated analyst rating and target; the rest (prior earnings date, prior insider sale, 13F-style ownership changes) is not a new event in this text.
Market effects
Limited read-across for rare-disease small-molecule/ion-channel biopharma; this is single-name sentiment rather than sector data.
No clear regional spillover beyond US small-cap biotech sentiment.
Minimal; no international deal/regulatory/clinical milestone disclosed.
Counterpoint
The article also cites a Sell rating from Weiss and a downgrade-to-sell from Wall Street Zen, suggesting the stock’s valuation may remain contested despite one Buy reiteration.
Key entities
- companyEdgewise Therapeutics
NASDAQ-listed clinical-stage biopharmaceutical company; subject of the analyst rating and target update.
- analyst_firmHC Wainwright
Reaffirmed a “buy” rating and reiterated a $45 price objective in a report released Tuesday.
